Nonclinical regulatory considerations for wound-healing growth factors
- 1 January 1990
- journal article
- research article
- Published by Wiley in Drug Development Research
- Vol. 19 (3) , 275-283
- https://doi.org/10.1002/ddr.430190306
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Preclinical and pharmacology and toxicology of hematopoietic growth factorsBiotechnology Advances, 1989
- Nonclinical pharmacologic and toxicologic considerations for evaluating biologic productsRegulatory Toxicology and Pharmacology, 1989
- In vivo incisional wound healing augmented by platelet-derived growth factor and recombinant c-sis gene homodimeric proteins.The Journal of Experimental Medicine, 1988
- The biology of platelet-derived growth factorCell, 1986
- Vasoconstriction: A New Activity for Platelet-Derived Growth FactorScience, 1986
- Platelet-derived growth factor in vivo: levels, activity, and rate of clearanceBlood, 1984
- PLATELET-DERIVED GROWTH-FACTOR INVIVO - LEVELS, ACTIVITY, AND RATE OF CLEARANCE1984
- Polypeptide Transforming Growth Factors Isolated from Bovine Sources and Used for Wound Healing in VivoScience, 1983
- Dual control of cell growth by somatomedins and platelet-derived growth factor.Proceedings of the National Academy of Sciences, 1979
- Respiratory gas tensions and pH in healing woundsThe American Journal of Surgery, 1967